html5-img
1 / 8

Featured Article :

Featured Article :. Long-Term Safety, Tolerability, and Weight Loss Associated With Metformin in the Diabetes Prevention Program Outcomes Study. THE DIABETES PREVENTION PROGRAM RESEARCH GROUP*. Diabetes Care Volume 35: 731-737 April, 2012. Study Objective.

trent
Télécharger la présentation

Featured Article :

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Featured Article: Long-Term Safety, Tolerability, and Weight Loss Associated With Metformin in the Diabetes Prevention Program Outcomes Study THE DIABETES PREVENTION PROGRAM RESEARCH GROUP* Diabetes Care Volume 35: 731-737 April, 2012

  2. Study Objective • Metformin produced weight loss and delayed or prevented diabetes in the Diabetes Prevention Program (DPP) • Study examined its long-term safety and tolerability along with weight loss, and change in waist circumference during the DPP and its long-term follow-up THE DIABETES PREVENTION PROGRAM RESEARCH GROUP* et al. Diabetes Care 2012;35:731-737

  3. Study Design • Randomized double-blind clinical trial of metformin or placebo in participants with IGT followed by a 7–8-year open-label xtension • Analysis of adverse events, tolerability, and effect of adherence on change in weight and waist circumference THE DIABETES PREVENTION PROGRAM RESEARCH GROUP* et al. Diabetes Care 2012;35:731-737

  4. THE DIABETES PREVENTION PROGRAM RESEARCH GROUP* et al. Diabetes Care 2012;35:731-737

  5. THE DIABETES PREVENTION PROGRAM RESEARCH GROUP* et al. Diabetes Care 2012;35:731-737

  6. THE DIABETES PREVENTION PROGRAM RESEARCH GROUP* et al. Diabetes Care 2012;35:731-737

  7. THE DIABETES PREVENTION PROGRAM RESEARCH GROUP* et al. Diabetes Care 2012;35:731-737

  8. Conclusions • Metformin used for diabetes prevention is safe and well tolerated. Weight loss is related to adherence to metformin and is durable for at least 10 years of treatment THE DIABETES PREVENTION PROGRAM RESEARCH GROUP* et al. Diabetes Care 2012;35:731-737

More Related